UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~July~~ 22September 24, 2015

Islet Sciences, Inc.

(Exact Name of Registrant as Specified in Charter)

Nevada	001-34048	87-0531751
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

6601 Six Forks Rd., Suite 140

Raleigh, North Carolina 27615

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (919) 480-1518

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

OnElection ~~July 22, 2015 Mr. Steven Delmar resigned as Chief Financial Officer~~ of ~~Islet Sciences, Inc~~Directors.~~, a Nevada corporation (the “Company”), and all subsidiaries effective August 15, 2015.~~

On ~~July~~September 2324, 2015, MrIslet Sciences, Inc. (the ~~James~~“Company”) ~~Green~~received ~~resigned~~a asstockholder ~~Chief~~written ~~Executive~~consent ~~Officer~~in lieu of ~~Islet~~an ~~Sciences,~~annual ~~Inc.,~~meeting from representatives of a ~~Nevada~~majority ~~corporation~~of its stockholders (the “Written Consent”). The Written Consent resolved to elect directors to the Company’s board of directors (the “Board”), and ~~all~~included ~~subsidiaries~~consents ~~effective~~from ~~August~~stockholders 22representing 36,279,581 ~~2015~~shares, or 54. 64%, of the outstanding shares of the Company’s common stock. Pursuant to the Written Consent, the following individuals were elected to the Board, with immediate effect: Larry K. Ellingson, Eugene M. Mannheimer, Richard D. Pilnik, Gary R. Keeling and James A. Harper, with Mr. Ellingson elected Chairman of the Board. The ~~termination~~Written ~~was~~Consent ~~for~~further resolved that Messrs. Ellingson, Mannheimer, Pilnik, Keeling and Harper (collectively, the “~~Good~~New ~~Reason~~Directors”) aswere ~~defined~~to ~~within~~succeed ~~his~~James ~~employment~~Green, ~~agreement~~William T. Mr Wilkison, James Snapper, Antonio O’Ferral and Larry Hutchison (collectively, the “Prior Directors”) as directors. ~~Green~~Pursuant ~~did~~to ~~not~~the ~~resign~~Company’s ~~from~~amended and restated bylaws, the ~~board~~terms of ~~directors~~each of the Prior Directors expired upon the election and qualification of their successors, the New Directors. John Steel was not succeeded by a New Director and shall remain a director until he resigns, is replaced, removed or otherwise terminated.

OnAppointment ~~July 23, 2015 Dr. William Wilkison resigned as Chief Operating Officer~~ of ~~Islet~~Larry ~~Sciences, Inc~~K., aEllingson ~~Nevada corporation (the “Company”),~~ and ~~all~~James ~~subsidiaries effective August 22, 2015~~A. ~~The~~ ~~termination was for “Good Reason” as defined within his employment agreement~~Harper. ~~Dr. Wilkison did not resign from the board of directors.~~

~~Item~~Larry 8K.01 ~~Other~~Ellingson, 69, was appointed President and Chief Executive Officer of the Company on September 24, 2015. Mr. Ellingson has not previously held a position with the Company or any of its subsidiaries.

InMr. ~~late~~Ellingson ~~June~~is ~~2015,~~the aChairman ~~lawsuit~~of ~~was~~the ~~brought~~Board ~~against~~of the Company, bywith ~~certain~~more ~~shareholders~~than ~~(petitioners),~~40 inyears ~~the~~of ~~District~~experience ~~Court,~~in ~~Clark~~management ~~County~~and ~~Nevada~~operations related to ~~compel~~ the ~~Company~~biotechnology toindustry. ~~have~~Mr. aEllingson ~~shareholder~~began ~~meeting~~his career at Eli Lilly and ~~for~~Company ain ~~temporary~~1971 ~~restraining~~and ~~order~~served as ~~set~~Executive ~~forth~~Director inof ~~the~~Diabetes ~~Company’s~~Care ~~Current~~at ~~Report~~Eli onLilly ~~Form~~and ~~8-K~~Company ~~filed~~until ~~with~~his ~~the~~retirement ~~SEC~~in on2001. ~~July~~From 152002 to 2005, ~~2015~~Mr. ~~After~~ aEllingson ~~hearing,~~served as the ~~court~~Executive ~~ordered~~Committee ~~that~~and Chairman of the ~~Company~~Board ~~hold~~of the American Diabetes Association. From 2005 to 2009 Mr. Ellingson served as Chairman and Chief Executive Officer of Protemix, Ltd., a ~~shareholder~~New ~~meeting~~Zealand ~~for~~biotechnology firm. From 2010 to 2012, he served on the ~~purpose~~Executive Committee of ~~electing~~the ~~directors~~International toDiabetes beFederation ~~held~~BRIDGES inProject. ~~New~~From ~~York~~2012 to the present, ~~New~~Mr. ~~York~~Ellingson ~~within~~has ~~sixty~~served ~~days~~as (i) a Co-Founder and ~~agreed~~Board toMember on the ~~petitioners~~National ~~request~~Diabetes ~~for~~Volunteer Leadership Council; (ii) a ~~temporary~~Committee ~~restraining~~Member ~~order.~~on Inthe ~~light~~National Income Development Committee of the ~~court~~American ~~ordered~~Diabetes ~~shareholder~~Association; ~~meeting~~ and ~~temporary~~(iii) ~~restraining~~a ~~order,~~Member of the ~~Company~~Scientific ~~was~~Advisory ~~unable~~Board toof ~~continue~~CHD ~~its~~Bioscience. ~~then~~Since ~~ongoing~~2013, ~~financing~~he ~~activities~~has ~~which~~served ~~was~~as ~~necessary~~Chairman toof ~~make~~ the ~~license~~Scientific Advisory Board for ~~Remogliflozin~~Boston ~~effective,~~Therapeutics. toMr. ~~provide~~Ellingson ~~operating~~is ~~funds~~currently ~~for~~principal ~~the~~of ~~Company~~Global Diabetes Consulting, towhere ~~fund~~he ~~the~~has ~~development~~worked ~~pipeline~~since ~~and~~2006. toHe ~~pay~~earned ~~current~~an ~~liabilities~~executive MBA degree from Babson College in 1986 and ~~other~~received ~~obligations~~a Bachelor of Science degree in Pharmacy from North Dakota State University in 1969.

OnThere ~~July~~are ~~17,~~no ~~2015~~understandings ~~petitioners~~or inarrangements ~~Nevada~~between ~~filed~~Mr. aEllingson ~~notice~~and ofany ~~non-opposition~~other toperson ~~the~~pursuant ~~Company's petition~~to ~~for dissolution~~which ofMr. ~~the~~Ellingson ~~temporary~~was ~~restraining~~selected ~~order,~~to ~~stating~~serve inas ~~their~~President ~~court~~and ~~filings~~Chief ~~that~~Executive ~~their~~Officer. ~~primary~~There ~~motivation~~are inno ~~seeking~~relationships ~~injunctive~~between ~~relief~~Mr. ~~from~~Ellingson ~~the~~and ~~Court was to prevent~~ the Company ~~from~~or ~~taking~~any ~~actions~~of inits ~~raising~~subsidiaries ~~the~~that ~~$10~~would ~~million~~require ~~required~~disclosure ~~for~~pursuant ~~the license agreement~~ to ~~become~~Item ~~effective. Petitioners also notified the court of~~ 404(a) ~~reservation~~ of ~~rights~~Regulation ~~to seek reinstatement of the temporary restraining order in the event circumstances should change~~S-K.

~~The~~There ~~Company~~are isno ~~now~~material ~~without the vehicle for a financing strategy~~plans, ~~has~~contracts ~~run~~or ~~out~~arrangements ofto ~~funds~~which ~~and its officers have resigned~~Mr. ~~The~~ ~~Company~~Ellingson ~~has~~is ~~ceased~~a ~~ongoing~~party ~~operational~~or ~~activities~~in ~~as the Board attempts to find actionable strategies with~~ which tohe ~~move~~participates ~~the~~that ~~Company~~was ~~forward~~entered ~~given~~into ~~the~~or ~~limited~~had ~~assets~~a ~~and~~material ~~current~~amendment ~~financial~~in ~~condition. These~~connection ~~could~~with ~~include,~~his ~~but are not limited to~~appointments, ~~a sale~~ or ~~license~~any ofgrant ~~technology, finding a strategic partner, finding additional investors, selling the Company,~~ or ~~dissolution~~award ofto ~~the Company~~Mr. ~~There~~ isEllingson ~~no assurance that any of these~~ or ~~other~~modification ~~outcomes~~thereto, ~~will~~under beany ~~successful. There~~such isplan, acontract ~~significant~~or ~~risk~~arrangement ~~the~~in ~~Company~~connection ~~will~~with ~~not~~his ~~find a positive outcome~~appointments.

James A. Harper, 68, was appointed Chief Operating Officer and Secretary of the Company on September 28, 2015. Mr. Harper has not previously held a position with the Company or any of its subsidiaries.

Mr. Harper has more than 30 years’ experience in the Global Pharmaceutical and Medical Device Industries, serving in a variety of senior executive and management positions at public companies such as Eli Lilly and Company, where he served as President of the Diabetes and Growth Disorders Product Group/Endocrine Business Unit from 1994 to 2001 and as Group Vice President of Global Marketing and Sales and Chief Marketing Officer from 2001 to 2004. Mr. Harper was also President and Chief Executive Officer of Advanced Cardiovascular Systems, Inc. from 1991 to 1993. Mr. Harper served on the board of directors of Phenomix Corporation from 2007 to 2013, including as Chairman from 2011 to 2013, and on the board of directors of Cornerstone Therapeutics, Inc. from 2011 to 2014. Mr. Harper holds a Master of Business Administration from the Wharton School of Business in Marketing and Finance (1973) and a Bachelor of Arts degree in Biology from Vanderbilt University (1969).

There are no understandings or arrangements between Mr. Harper and any other person pursuant to which Mr. Harper was selected to serve as Chief Operating Officer and Secretary. There are no relationships between Mr. Harper and the Company or any of its subsidiaries that would require disclosure pursuant to Item 404(a) of Regulation S-K.

There are no material plans, contracts or arrangements to which Mr. Harper is a party or in which he participates that was entered into or had a material amendment in connection with his appointments, or any grant or award to Mr. Harper or modification thereto, under any such plan, contract or arrangement in connection with his appointments.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The information required by Item 5.07 relating to the submission of matters to a vote of security holders is contained in Item 5.02 of this Current Report on Form 8-K and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Islet Sciences, Inc.
Dated: July 27, 2015	By:	/s/ Steven R. Delmar
Dated: September 30, 2015	By:	/s/ Larry K. Ellingson
		Name: Steven R. Delmar
		Name: Larry K. Ellingson
		Title: Chief Financial Officer
		Title: Chairman, Chief Executive Officer and President

Filing Compare · Islet Sciences, Inc.